Search Results
ID: /D2n9Spk/biz/60527899#60528070
6/20/2025, 10:05:37 PM
>>60527949
Like with any biotech, it's a lottery ticket.
Galectin Therapeutics is in Phase 2/3 in a clinical trial for treatment of MASH w/o esophageal varices (think varicose veins but in the esophagus). It does not work in patients who are so far gone that their esophagus is about to blow open and the patient bleeds to death. It's supposed to prevent those blood vessels from getting that large in the first place. The market is huge because it generally requires being a fat fuck to get that disease.
The study completes 2025-09-30. If it fails, prepare for a massive dump that'll probably bankrupt the company. If it succeeds, it'll be the very first effective treatment against MASH cirrhosis, and essentially be the ozempic for people who are too far gone to benefit from ozempic.
Extremely high risk, questionable reward. Sounds like /smg/'s favorite type of stock.
Like with any biotech, it's a lottery ticket.
Galectin Therapeutics is in Phase 2/3 in a clinical trial for treatment of MASH w/o esophageal varices (think varicose veins but in the esophagus). It does not work in patients who are so far gone that their esophagus is about to blow open and the patient bleeds to death. It's supposed to prevent those blood vessels from getting that large in the first place. The market is huge because it generally requires being a fat fuck to get that disease.
The study completes 2025-09-30. If it fails, prepare for a massive dump that'll probably bankrupt the company. If it succeeds, it'll be the very first effective treatment against MASH cirrhosis, and essentially be the ozempic for people who are too far gone to benefit from ozempic.
Extremely high risk, questionable reward. Sounds like /smg/'s favorite type of stock.
Page 1